LPV/r oral sol.80+20mg/ml/BOT-5x60ml
Lopinavir 80mg/ml + Ritonavir 20mg/ml oral solution, 5 bottles each of 60ml, with oral dispensing device.
Indicative Price : Upon Request
NOTE: The description below is for a standard product. It is not specific to patent status and pricing policies that may apply at country level. This information is available on request from Supply Division: Contact: firstname.lastname@example.org
Lopinavir (LPV) 80mg/ml + Ritonavir (RTV) 20mg/ml oral solution, 5 bottles of 60ml
Each 1ml oral solution contains a boosted protease inhibitor combination of Lopinavir 80mg + Ritonavir 20mg
Protease Inhibitors (PI)
Standard shelf life:
Route of Administration:
By mouth (oral)
Other available formulations:
The product may also be available in other formulations, pack sizes, or in combinations with other ARVs.
Guidelines for use:
For more details, please click the links listed below:
WHO treatment guidelines
WHO Essential Medicines Library
or your regional national guidelines
For details about paediatric dosage schemes, please click the links listed below:
WHO Generic tool for assessing paediatric ARV dosing
Management of HIV-1 infection in infected adults and children above 2 years of age in combination with at least two other antiretroviral drugs. Administration: Per mouth (PO)
NOTE: Ritonavir increases effect of Lopinavir; it is used in this co-formulation as a booster to Lopinavir and this low dose in combination does not have intrinsic antiviral activity
Store between 2ºC-8ºC (refrigerated) until dispensing. Do not freeze. After dispensing to be stored below 25ºC for no more than six weeks.
Dispense in original container. Do not repack
For latest updates, please click the links listed below:
List of WHO Prequalified Medicines
List of USFDA approved and tentatively approved items
Please click on the link:
Important information regarding supply for this product
|To see icon descriptions, go to |
' Product attribute guide'